Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256484 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTRENITGB3ITGA2B | |
| SCHEMBL18256448 | 0.92 | ALDH1A1 (0.46) | ALDH1A1MAPTRENITGB3ITGA2B | |
| SCHEMBL23279537 | 0.92 | ALDH1A1 (0.46) | ALDH1A1MAPTRENITGB3ITGA2B | |
| SCHEMBL21447888 | 0.91 | MMP12 (0.39) | RENCTSSCTSKMME | |
| SCHEMBL18256552 | 0.91 | ITGB3 (0.40) | ALDH1A1RENITGB3ITGA2BCTSS | |
| SCHEMBL18248115 | 0.91 | ITGB3 (0.40) | ALDH1A1RENITGB3ITGA2BCTSS | |
| SCHEMBL21447947 | 0.85 | CTSK (0.46) | MAPTRENCTSSCTSK | |
| SCHEMBL18248083 | 0.85 | CTSK (0.46) | MAPTRENCTSSCTSK | |
| SCHEMBL21447763 | 0.85 | CTSK (0.46) | MAPTRENCTSSCTSK | |
| SCHEMBL23269885 | 0.85 | MMP13 (0.39) | ALDH1A1MAPTRENCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286455-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3922639-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3298027-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3541789-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20180362589-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-10081656-B2 | Anthelmintic depsipeptide compounds | MERIAL, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| WO-2018093920-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-3298027-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Merial, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2016187534-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | ALDH1A1 3037/4885MAPT 4110/4885REN 4019/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | ALDH1A1 3183/4885MAPT 4752/4885REN 2157/4885 |
| US-20180362589-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | ALDH1A1 3037/4885MAPT 4110/4885REN 4019/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | ALDH1A1 3037/4885MAPT 4110/4885REN 4019/4885 |
| US-10081656-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | ALDH1A1 3037/4885MAPT 4110/4885REN 4019/4885 |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | ENPP2, ROCK2, RRP12 | ALDH1A1 3183/4885MAPT 4752/4885REN 2157/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | ALDH1A1 3037/4885MAPT 4110/4885REN 4019/4885 |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | ALDH1A1 3037/4885MAPT 4110/4885REN 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.